<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Capecitabine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01101</strong>&#160; (APRD00203)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits <span class="caps">DNA</span> synthesis and slows growth of tumor tissue.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01101/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01101/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01101.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01101.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01101.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01101.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01101.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01101">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Xeloda</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/prodrugs">Prodrugs</a></li></ul></td></tr><tr><th>CAS number</th><td>154361-50-9</td></tr><tr><th>Weight</th><td>Average: 359.3501<br>Monoisotopic: 359.149263656</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>6</sub></td></tr><tr><th>InChI Key</th><td>GAGWJHPBXLXJQN-UORFTKCHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Glycoamino Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Pyrimidine Nucleosides and Analogues; Pentoses; Pyrimidones; Halopyrimidines; Aminopyrimidines and Derivatives; Aryl Fluorides; Hydropyrimidines; Oxolanes; Tetrahydrofurans; Secondary Alcohols; Carbamic Acids and Derivatives; 1,2-Diols; Ethers; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>glycosyl compound; n-glycosyl compound; pentose monosaccharide; pyrimidone; halopyrimidine; aminopyrimidine; pyrimidine; hydropyrimidine; monosaccharide; saccharide; aryl halide; aryl fluoride; oxolane; tetrahydrofuran; 1,2-diol; secondary alcohol; carbamic acid derivative; ether; polyamine; organohalogen; amine; alcohol; organonitrogen compound; organofluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the glycoamino acids and derivatives. These are saccharides attached to a single amino acid by any kind of&#160;covalent bond. A glycosyl-amino-acid is a compound consisting of saccharide linked through a glycosyl linkage (O-,&#160;N-, or&#160;S-) to an amino acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.</td></tr><tr><th>Pharmacodynamics</th><td>Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity indicated for the treatment of metastatic breast cancer and colon cancer. It is an orally administered systemic prodrug that has little pharmacologic activity until it is converted to fluorouracil by enzymes that are expressed in higher concentrations in many tumors. Fluorouracil it then metabolized both normal and tumor cells to 5-fluoro-2&#8242;-deoxyuridine 5&#8242;-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP).</td></tr><tr><th>Mechanism of action</th><td>Capecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, therefore a deficiency of this compound can inhibit cell division. Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis through the production of fraudulent RNA.</td></tr><tr><th>Absorption</th><td>Readily absorbed through the GI tract (~70%)</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized by thymidine phosphorylase to fluoruracil.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Capecitabine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002705" target="_blank">Liver carboxylesterase 1</a></li>
<li><a href="/biodb/bio_entities/BE0002443" target="_blank">Cytidine deaminase</a></li></ul></td><td><a href="/metabolites/DBMET00656">5&#8217;-Deoxy-5-fluorouridine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/677">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00656">5&#8217;-Deoxy-5-fluorouridine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002193" target="_blank">Thymidine phosphorylase</a></li></ul></td><td><a href="/metabolites/DBMET00449">5-fluorouracil</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1282">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose.About 3% of the administered dose is excreted in urine as unchanged drug.</td></tr><tr><th>Half life</th><td>45-60 minutes for capecitabine and its metabolites.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Capecitabine Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00469?highlight%5Bcompounds%5D%5B%5D=DB01101&amp;highlight%5Bproteins%5D%5B%5D=DB01101">SMP00469</a></td></tr><tr><td>Capecitabine Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00607?highlight%5Bcompounds%5D%5B%5D=DB01101&amp;highlight%5Bproteins%5D%5B%5D=DB01101">SMP00607</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9513</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6064</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7096</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5106</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8234</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7514</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9654</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7999</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.864</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7523</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7673</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8612</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6569</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7404</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8484</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6521
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8754
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9964
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4690 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9759
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7124
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Hoffmann la roche inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Dept Health Central Pharmacy</li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Xeloda 500 mg tablet</td><td>28.97USD</td><td>tablet</td></tr><tr><td>Xeloda 150 mg tablet</td><td>8.69USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5472949</td><td>1993-12-14</td><td>2013-12-14</td></tr><tr><td>United States</td><td>4966891</td><td>1994-01-13</td><td>2011-01-13</td></tr><tr><td>Canada</td><td>2103324</td><td>1997-12-23</td><td>2013-11-17</td></tr><tr><td>Canada</td><td>1327358</td><td>1994-03-01</td><td>2011-03-01</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>110-121 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>26 mg/mL</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>0.4</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.48e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.17</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>0.77</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>8.23</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-3.6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>120.69</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>82.75</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>35.81</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p><a href="http://www.drugsyn.org/Capecitabine.htm">DrugSyn.org</a></p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5472949&amp;tbm=pts" target="_blank">US5472949 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Walko CM, Lindley C: Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15763604">Pubmed</a></li>
	<li>Wagstaff AJ, Ibbotson T, Goa KL: Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63(2):217-36. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12515569">Pubmed</a></li>
	<li>Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H, Kouvaris J: Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules. 2008 Aug 27;13(8):1897-922. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18794792">Pubmed</a></li>
	<li>Twelves C: Vision of the future: capecitabine. Oncologist. 2001;6 Suppl 4:35-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11585973">Pubmed</a></li>
	<li>Milano G, Ferrero JM, Francois E: Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer. 2004 Aug 16;91(4):613-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15280932">Pubmed</a></li>
	<li>de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11291832">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D01223" target="_blank">D01223 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C12650" target="_blank">C12650 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60953" target="_blank">60953 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508686" target="_blank">46508686 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.54916.html" target="_blank">54916 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=31348" target="_blank">31348 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1773" target="_blank">CHEMBL1773 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000761" target="_blank">DAP000761 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA448771" target="_blank">PA448771 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2238454" target="_blank">2238454 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/capecitabine.htm" target="_blank">http://www.rxlist.com/cgi/generic3/capecitabine.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/capecitabine.html" target="_blank">http://www.drugs.com/cdi/capecitabine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Capecitabine" target="_blank">Capecitabine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L01BC06<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L01#L01">L01 &#8212; ANTINEOPLASTIC AGENTS</a></li><li><a href="/atc/L01B#L01B">L01B &#8212; ANTIMETABOLITES</a></li><li><a href="/atc/L01BC#L01BC">L01BC &#8212; Pyrimidine analogues</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>10:00.00</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01101.pdf?1265922801">show</a>(133 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Capecitabine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Capecitabine may increase the anticoagulant effect of anisindione by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Capecitabine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Capecitabine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Capecitabine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Capecitabine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Capecitabine increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Capecitabine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Capecitabine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Capecitabine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The strong CYP2C9 inhibitor, Capecitabine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Capecitabine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if capecitabine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect.</td></tr><tr><td><a href="/drugs/DB00549">Zafirlukast</a></td><td>Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if capecitabine is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take 12 hours apart, within 30 minutes of the end of breakfast and dinner to reduce nausea.</li></ul></td></tr></tbody></table>